Xeris Biopharma Holdings, Inc. (0A8E.L)
LSE · USD
$10.38 (+2.32%) as of
Key statistics
- EPS (TTM)
- -1.42
- 52-week range
- 1.28 – 10.46
- Beta
- 0.84
- Revenue (TTM)
- 335.41M
- Profit margin
- -5.12%
- Volume
- 1.89k
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Headquarters
- Chicago, IL, United States
- Employees
- 435
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.